Upon the recommendation of the Nominating & Corporate Governance Committee of the Board of Directors (the “Board”) of Augmedix, Inc., a Delaware corporation (the “Company”), on April 10, 2023, the Board appointed Robert Faulkner to serve as a Class III director, effective as of April 14, 2023. The term of each Class III director of the Company will expire at the Company's 2023 annual meeting of stockholders unless such director is re-elected for a new three-year term. Mr. Faulkner has been a Managing Director at Redmile Group, LLC, a health care-focused investment firm, since February 2008.

Mr. Faulkner has served on the board of directors of MedAvail Holdings, Inc. (MedAvail) since November 2020 and as chairman of MedAvail's board of directors since January 2022, as well as the Chairman of the board of directors of Science 37 Holdings, Inc. since October 2021. Prior to Redmile, Mr. Faulkner was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.) and SG Warburg & Co. (now UBS).

Mr. Faulkner holds an A.B. from Harvard College and an MBA from the Tuck School of Business at Dartmouth College.